Taro Pharmaceuticals

What Taro Pharmaceuticals does

Taro Pharmaceutical Industries is a research-based international pharmaceutical company founded in 1950 in Haifa, Israel, that develops, manufactures, and markets generic prescription (Rx) and over-the-counter (OTC) pharmaceutical products. The company's product portfolio spans dermatology, cardiology, pediatrics, and neurology therapeutic areas, delivered through diverse dosage forms including tablets, capsules, suspensions, solutions, creams, and ointments, including proprietary products such as Pliaglis (lidocaine/tetracaine 7%/7% topical anesthetic) and the TaroPharma branded division established in 2003. Taro operates a vertically integrated manufacturing model with in-house active pharmaceutical ingredient (API) synthesis, with production facilities in Haifa (Israel), Brampton (Canada), and Hawthorne, New York, all FDA-approved and GMP-compliant.

Taro sells through a B2B sales-led go-to-market model, distributing generic Rx and OTC products via pharmacy channels, wholesale distributors, and private-label arrangements with retail chains in the US, Canada, Israel, and international markets. Customer segments include healthcare professionals (physicians, pharmacists), patients and consumers, and retail pharmacies and distributors. Revenue is generated through one-time sales of generic pharmaceutical products and API supply through its Taro API division, with pricing varying by market, dosage, pack size, and contractual terms rather than publicly disclosed schedules. Taro also partners with the non-profit Rx Outreach on a Patient Assistance Program for select critical medications. Since June 24, 2024, Taro has been a privately held, wholly-owned subsidiary of Sun Pharmaceutical Industries following a $454 million merger that ended its NYSE listing.

Name

Taro Pharmaceuticals

Legal name

Taro Pharmaceuticals U.S.A., Inc.

Website

http://www.taro.com/

Company type

Private

Founded year

1950

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Taro Pharmaceutical Industries is a research-based generic pharmaceutical manufacturer founded in 1950 that develops, produces, and distributes prescription and OTC medicines across dermatology, cardiology, pediatrics, and neurology for healthcare professionals, pharmacies, and consumers in the US, Canada, Israel, and international markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Generic pharmaceuticals
• Over-the-counter medications
• Topical formulations
• Active pharmaceutical ingredients
• Dermatology products

Headquarters

HQ city

Haifa

HQ country

Israel

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Sales: Revenue generated from manufacturing and selling generic prescription (Rx) and over-the-counter (OTC) pharmaceutical products across dermatology, cardiology, pediatrics, and neurology therapeutic areas. Products distributed in US, Canada, Israel and international markets.
2. Active Pharmaceutical Ingredient (API) Sales: Taro synthesizes APIs internally and offers them through Taro API division for internal product use and external commercial supply.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

Taro Pharmaceutical Industries develops, manufactures, and markets generic prescription and over-the-counter pharmaceutical products across dermatology, cardiology, pediatrics, and neurology therapeutic areas. The company operates a vertically integrated manufacturing model with in-house API synthesis and produces tablets, capsules, suspensions, solutions, creams, and ointments. Taro also markets a proprietary topical anesthetic (Pliaglis) and supplies APIs and finished dosage forms to the U.S., Canada, Israel, and international markets.

Product overview

Taro Pharmaceutical Industries is a research-based international pharmaceutical company that develops, manufactures, and markets generic prescription and over-the-counter medications. The company operates across four primary therapeutic areas: dermatology (topical corticosteroids, antifungals, and combination therapies), cardiology (cardiovascular drugs including Warfarin and Amiodarone), neurology (anticonvulsants including Carbamazepine and Phenytoin), and pediatrics (liquid formulations). Taro's product portfolio includes tablets, capsules, suspensions, solutions, creams, and ointments, with vertical integration through in-house Active Pharmaceutical Ingredient (API) synthesis. The company markets products under Taro label and private label in the U.S., Canada, Israel, and international markets. Since June 2024, Taro has been a privately held, wholly-owned subsidiary of Sun Pharmaceutical Industries following a $454 million merger.

Differentiator

Problem solved

Functional benefit

Brands

• Pliaglis: Topical local anaesthesia cream containing lidocaine and tetracaine for superficial dermatological procedures

Products and services

• Pliaglis (Lidocaine and Tetracaine 7%/7% Cream)
• Generic Prescription Products (Dermatology)
• Generic Prescription Products (Cardiology)
• Generic Prescription Products (Neurology)
• Generic Prescription Products (Pediatrics)
• Generic OTC Products (USA)
• Generic OTC Products (Canada)
• Active Pharmaceutical Ingredients (APIs)
• TaroPharma Branded Division Branded division established in 2003 in the U.S. for proprietary pharmaceutical products, providing a brand-name commercial vehicle alongside Taro's generic portfolio.

Quantifiable outcome

• Over $1 billion gross sales achieved (IMS Calendar Year 2012)

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered minor.

• Rx OutreachminorStrategic or Co-development PartnerTaro partners with the non-profit organization Rx Outreach to provide a Patient Assistance Program offering critically needed medications to eligible patients who cannot afford them.
• Antibe TherapeuticsminorStrategic or Co-development PartnerSun Pharma subsidiary Taro planned to acquire 100% of Antibe Therapeutics, a biotechnology company in Ontario, Canada specializing in pain and inflammation management. The acquisition was expected to close before March 7, 2025 pending court approval. Antibe currently reports no revenue and is under court-appointed receivership.
• Strides Pharma Inc.minorOEM/ Whitelabel/ Licensing PartnerStrides Pharma Inc., an India-based contract manufacturer, manufactures Taro's Children's Ibuprofen Oral Suspension products under a manufacturing agreement. Strides initiated a product recall in March 2026 following customer complaints about contamination.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Perrigo Company: Perrigo is a US-based generic and OTC pharmaceutical company with a particularly strong dermatology/skin care portfolio. Directly comparable on generic Rx and OTC distribution through US retail pharmacy chains, private label programs, and topical formulation capabilities.
• Apotex Inc. Apotex is the largest Canadian generic pharmaceutical manufacturer, headquartered near Toronto. Directly comparable on Canadian manufacturing footprint, broad generic Rx/OTC portfolio, and emphasis on affordable access.
• Amneal Pharmaceuticals: Amneal is a US-focused generic and specialty pharmaceutical manufacturer with a broad portfolio spanning injectables, topicals and oral solids. Comparable on multi-therapeutic-area generic strategy and US retail/wholesale distribution.
• Lannett Company: Lannett is a US-focused generic pharmaceutical manufacturer with a broad solid-oral and topical portfolio. Comparable as a smaller-cap US generic competitor serving pharmacy chains and wholesalers.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is the world's largest generic manufacturer and Israel's flagship pharma company. Comparable on generic Rx across dermatology, neurology, and cardiology; Taro has historically been a smaller Israeli peer with overlapping therapeutic-area focus.
• Aurobindo Pharma: Aurobindo is one of India's largest generic manufacturers with strong US presence. Comparable on generic Rx breadth, dermatology/topicals, neurology portfolio, and vertical API integration.
• Sandoz (Novartis): Sandoz is the global generic and biosimilar arm of Novartis, with extensive US, Canadian, and European operations. Comparable across the full generic Rx/OTC spectrum including dermatology, cardiology and neurology therapeutic categories.
• Viatris (formerly Mylan): Viatris is a leading global generic and specialty pharma formed via Mylan/Upjohn merger. Comparable as a broad-line generic player across dermatology, neurology, and cardiology with worldwide distribution.

Others

• Sun Pharmaceutical Industries: Sun Pharma is Taro's parent company and India's largest pharma company. While not a competitor (Taro is its subsidiary), Sun Pharma is thematically related as a vertically integrated generic manufacturer with comparable dermatology/specialty ambitions and is a key direct peer for portfolio and capability benchmarking.

Emerging players

• Endo International: Endo (including its Par Pharmaceuticals generics segment) has historically been a direct US generic competitor with strength in dermatology/topicals, injectables and controlled substances. Comparable on retail pharmacy-channel generics competition.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/taro-pharmaceuticals

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taro Pharmaceuticals